Category: Asset

  • Harmony Acquires ConSynance’s Asset for the Treatment of Narcolepsy and other Rare Neurological Diseases

    Shots: Harmony to receive $3.5M up front & development and regulatory milestone along with royalties & will acquire full development and commercialization rights globally, Ex- Greater China The acquisition of HBS-102 marks a next-generation therapy after Wakix (pitolisant). Additionally, Harmony plans to build a robust portfolio to treat patients with rare neurological diseases & continue […]

  • Fusion to Acquire Ipsen’s IPN-1087 to Expand its Pipeline of Radiopharmaceuticals

    Shots: Ipsen to receive 400,000 shares at closing and an additional 200,000 shares as milestones, $81.63M as development and regulatory milestones & $423.24M as commercial milestones along with royalties on net sales Fusion will be responsible for paying to a third-party licensor up to $84.7M in development milestones and royalties on net sales of products […]